

ACTELION'S FINANCE

THE FIRST QUARTER 2012

SUMMARY


On 19 April 2012, Actelion announced its financial results for the first quarter of 2012. With total net revenues of CHF 417.5 million (Q1 2011: CHF 528.2 m) and operating expenses of CHF 350.3 million (Q1 2011: CHF 363.6 m), the company reported a first quarter 2012 operating profit of CHF 67.1 million (Q1 2011: CHF 164.7 m).

For the same period, Actelion reported a core earnings of CHF 107.6 million, a decrease of 16 percent compared to first quarter of 2011. Core earnings are defined as product sales minus Non-GAAP operating expenses. In local currencies, Core Earnings decreased by 9 percent. Adjusted (non-US GAAP) diluted earnings per share for 2011 were CHF 0.70 compared to CHF 1.53 during the same period last year.

On a US GAAP basis, net income for the first quarter 2012 was CHF 45.1 million (Q1 2011: CHF 146.3 m). Fully diluted earnings per share on a US GAAP basis for the same period was CHF 0.38, compared to CHF 1.20 for the first quarter 2011.

NET REVENUES


CHF million



Product sales for the first quarter of 2012 were CHF 415.8 million (Q1 2011 CHF 450.1 million), a decrease of 4% in local currencies. Contract revenues for the same period amounted to CHF 1.6 million (Q1 2011: CHF 78.1 m).

OPERATING EXPENSES

CHF million




Total operating expenses for the first quarter 2012 were CHF 350.3 million compared to CHF 363.6 million for the first quarter of 2011, a decrease of 4 %.

Research and Development (R&D) expenses in the first quarter of 2012 were up 8 % to CHF 129.9 million (Q1 2011: CHF 120.7 million). This increase was entirely driven by a USD 10 million milestone payment to Auxilium Pharmaceuticals, related to the collaboration the two companies announced in February 2012 for XIAPLEX in Canada, Australia, Brazil and Mexico.


Selling, General and Administrative expenses (SG&A) for the first quarter of 2012 were CHF 161.9 million (Q1 2011: CHF 181.4 million), representing a decrease of 11 %.

OPERATING INCOME



Operating income for the first quarter 2012 was CHF 67.1 million compared to CHF 164.7 million for the same period in 2011, a decrease of 59%. In local currencies operating income decreased by 54 %.


CORE EARNINGS



In order to better compare the company's underlying performance, Actelion reports core earnings as product sales minus cash operating expenses, as well as other items that may distort comparison.

For the first quarter of 2012, core earnings amounted to CHF 107.6 million compared to CHF 127.9 million during the first quarter of 2011. This represents a decrease of 9 % in local currencies.

NET INCOME (LOSS)



Net income for the first quarter 2012 amounted to CHF 45.1 million (Q1 2011: CHF 146.3 million). This represents a decrease of 69 % in Swiss Franc terms or 64 % in local currencies.

Net income for the period includes interest income of CHF 0.5 million, interest expense of CHF 0.4 million, interest expense on the litigation provision of CHF 9.4 million, interest expense on the Swiss Franc bond of CHF 3.0 million, impairment of financial assets of CHF 0.3 million related to Greek bonds, and other financial expense of CHF 0.9 million related to hedging and valuation gains and losses.

Income tax expense for the first quarter amounts to CHF 8.6 million which translates into a tax rate of 16 percent.

US GAAP earnings per share on a fully diluted basis in the first quarter 2012 decreased by 68 % compared to the same period a year ago to CHF 0.38 whilst core earnings per share decreased by 31 % to CHF 0.66.

BALANCE SHEET

Total assets of Actelion at 31 March 2012, were CHF 2.65 billion.

FINANCIAL OVERVIEW

In CHF million	Q1 2012	Q1 2011	in %	in %
	Results	Results	CHF	LC
Net Revenues	417.5	528.2	(21)	(18)
Operating Expenses	350.3	363.6	(4)	(2)
Operating Income	67.1	164.7	(59)	(54)
Core Earnings	107.6	127.9	(16)	(9)
Net Income / (Loss)	45.1	146.3	(69)	(64)
Diluted EPS in CHF	0.38	1.20	(68)	(63)
No of shares in calculation	118.9	122.1		

The full financial statements can be found on <http://www.actelion.com>

SHARE PRICE DEVELOPMENT OVER 12 MONTHS



Stock charting tools available at www.actelion.com

ACTELION LTD – SHARE AT A GLANCE

The registered shares of Actelion Ltd were second listed on the SWX New Market on April 6, 2000 (symbol: ATLN). A total of 1,000,000 primary shares were placed at the company's Initial Public Offering (IPO), at a price of CHF 260 per share, raising CHF 246.6 million.

On 22 November 2006, Actelion Finance SCA, Luxembourg issued CHF 460 million of senior convertible bonds due 2011 unconditionally and irrevocably guaranteed by Actelion Ltd, Allschwil, Switzerland. The bonds have a coupon of zero percent and an annual yield to maturity of zero percent. The conversion price is CHF 53.21 (adjusted for the CHF 0.80 dividend payment paid on 11 May 2011). On or after 30 June 2007 and until the 30th trading day prior to the maturity date on 22 November 2011, each Bond in the denomination of CHF 5,000 is convertible free of charge into cash up to the principal amount and any conversion value above the principal amount may be settled, at the option of Actelion, into cash or Shares or a combination thereof. The issue price was set at 100% and the redemption price at 100%. The bonds were redeemed on 22 November 2011 and the bonds were settled in cash.

On 8 July 2008, the Management Committee of the SIX Swiss Exchange decided to add Actelion shares (ATLN, CH0010532478) to the Swiss Market Index SMI®. Actelion shares have traded as part of the SMI since 22nd September 2008.

Actelion Pharmaceuticals Ltd is a global biopharmaceutical company headquartered in Allschwil/Basel, Switzerland. Actelion concentrates on discovering, developing and marketing innovative drugs for high unmet medical needs. The company is quoted on the SIX Swiss Exchange (ticker symbol: ATLN).

In November 2010, Actelion commenced the repurchase of up to CHF 800 million of the company's common stock over the next three years via a second trading line on the SIX Swiss exchange. At subsequent Annual General Meetings, the Board of Directors will propose that the shares bought through this process be cancelled and the issued share capital reduced accordingly.

On 7 December 2011, Actelion Ltd raised CHF 235 million through a 4 year, 4.875% Swiss Franc bond.

Issue price was 100.25%. The bonds will mature on 7 December 2015 at par. The coupon of the bonds is subject to Swiss withholding tax of 35%.

Actelion Ltd is part of the following indices: SMI, SPI, SLI, SPIMLC, SPI20, SPISMC, SXXP, SXDP, SBC100, SNSPIX, SMHCAX, SLDI, SXI LIFE SCIENCES and SXI Bio+Medtech. Actelion is traded under the following symbols: Reuters: ATLN.S/ Bloomberg ATLN.

KEY SHARE DATA

As of 31.03.2012:

Shares outstanding as of 31.03.2012	130.7 million
Closing share price as of 31.03.2012	CHF 33.00
Market capitalization as of 31.03.2012	CHF 4.3 billion
52-week high	CHF 55.30
52-week low	CHF 28.16
YTD price change	(2%)
Average daily volume	0.5 million
Free float	89.7%

SHAREHOLDINGS

As of 31.03.2012:

Number of registered shareholders	11,509
-----------------------------------	--------

Major shareholders

Actelion Ltd	> 10%
Management & Directors	> 5%
Orbis	> 5%
BB Biotech	> 3%
Rudolf Maag	> 3%
Lazard Asset Mgmt	> 3%

Latest update: April 2012

Disclaimer This fact sheet has the sole purpose to provide members of the public with general information about the activities of Actelion Ltd and its associated companies. The forward-looking statements in this fact sheet are based on current expectations and belief of company management, which are subject to numerous risks and uncertainties.